High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Significance: Nanoparticle-mediated delivery of siRNA to hepatocytes has treated disease in humans. However, systemically delivering RNA drugs to nonliver tissues remains an important challenge. To increase the number of nanoparticles that could be studied in vivo, we designed a high-throughput method to measure how >100 nanoparticles delivered mRNA that was translated into functional protein in vivo. We quantified how >250 lipid nanoparticles (LNPs) delivered mRNA in vivo, identifying two LNPs that deliver mRNA to endothelial cells. One of the LNPs codelivered Cas9 mRNA and single-guide RNA in vivo, leading to endothelial cell gene editing. This approach can identify nanoparticles that target new cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Such assemblies, complexed with polymers capable of disrupting endosomes and including DNA templates for homology-directed repair, were found to promote correction of dystrophin gene mutations in mice 80 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 1×
“To confirm protein silencing was mediated by gene editing, we measured (40) ICAM-2 insertions and deletions (indels) in lung, spleen, and kidney endothelial cells and found between 30 and 70% editing per locus, leading to overall ICAM-2 indel percentages of 135, 95, and 123% indel, respectively for 7C2 (Fig.”
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001 · cited 6×
“Next, C57BL/6J mice were injected two times with 2 mg/kg with 7C3 formulated to carry both SpCas9 mRNA (L-7206; Trilink Biotechnology) and e-sgICAM2 (AxoLabs) at a 1:1, 3:1, and 5:1 mass ratio.”
InfluentialSelf-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“Moreover, LNP siRNA delivery is often tested in vivo using the FVII assay, which predicts hepatocyte delivery; this assay is enhanced by its ease, as well as the fact that validated, potent siRNA targeting FVII is available (18, 19).”
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“In mice, nanoparticles have delivered Cas9 mRNA and ribonu-cleoproteins via systemic or local injection (5 – 12).”
Cited by
Items 201–300 of 312
mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics
Dalabehera, M., Ghosh, A., Mohanty, S., Chellappan, D. K., Chaudhari, S., Ale, Y., Poonia, N., Subudhi, R. N., Khanna, M., & Lim, H. G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102584 · Cited by 28
Hamilton, A. G., Thatte, A. S., Xu, J., Luo, Z., Safford, H. C., Swingle, K. L., Muscat-Rivera, J., Kegel, M., Han, X., Joseph, R. A., et al. (2026) · Advanced Materials · doi:10.1002/adma.202514370 · Cited by 24
Truong, L. B., Medina-Cruz, D., & Mostafavi, E. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125185 · Cited by 18
Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In Vivo mRNA Delivery
Samaridou, E., Simon, J., Beck‐Broichsitter, M., Davidson, G. R., & Levkin, P. A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501037 · Cited by 18
Versatility of LNPs across different administration routes for targeted RNA delivery
Jallow, M. B., Huang, K., & Qiu, M. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00575b · Cited by 18
Figueroa‐Espada, C. G., Guimarães, P. P. G., Riley, R., Xue, L., Wang, K., & Mitchell, M. J. (2023) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-023-00774-y · Cited by 14
Advances in techniques to characterize cell-nanomaterial interactions (CNI)
Huang, X., Li, X., & Tay, A. K. P. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102149 · Cited by 14
RNA encoded peptide barcodes enable efficient in vivo screening of RNA delivery systems
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S. G. T., Vashist, S., Snijder, H. J., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae648 · Cited by 19
Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle‐Based Gene Delivery Systems
Greco, A., & Corbo, C. (2025) · Small Science · doi:10.1002/smsc.202500206 · Cited by 13
Immune-Modulating Lipid Nanomaterials for the Delivery of Biopharmaceuticals
Kim, S., Choi, B., Kim, Y., & Shim, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061760 · Cited by 17
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 17
Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects
George, C. A., Sahu, S. U., de Oñate, L., Souza, B. S. D. F., & Wilson, R. C. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0036 · Cited by 19
Lipid nanoparticles for mRNA therapy: recent advances in targeted delivery
Wei, T., Tao, W., & Cheng, Q. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac004 · Cited by 16
The significance of bioengineered nanoplatforms against SARS-CoV-2: From detection to genome editing
Hassanzadeh, P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119289 · Cited by 14
High-throughput, AI-assisted design and optimization of lipid nanoparticles for drug delivery
Zeng, J., Chen, R., He, S., Zhang, C., Liu, W.-C., Song, H., Liu, S., & Nan, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114573 · Cited by 18
Noncoding RNA therapeutics for substance use disorder
Seyednejad, S. A., & Sartor, G. C. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10807 · Cited by 15
Therapeutic applications of cell engineering using mRNA technology
He, Y., Johnston, A. P. R., & Pouton, C. W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.07.012 · Cited by 14
Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation
Talemi, M. N., Farani, M. R., Eskandani, N. A., Mirzaee, D., Alipourfard, I., & Huh, Y. S. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102774 · Cited by 30
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
Liu, J., Fu, Q., Li, Q., Yang, Y., Zhang, Y., Yang, K., Sun, G., Luo, J., Lu, W., & He, J. (2024) · Pharmaceutical Fronts · doi:10.1055/s-0044-1786180 · Cited by 15
Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy
Alshehry, Y., Liu, X., Li, W., Wang, Q., Cole, J., & Zhu, G. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01051-8 · Cited by 19
Johnson, M. A., Klickstein, J. A., Khanna, R., Gou, Y., & Raman, M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105722 · Cited by 15
Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science
Abdeen, A. A., Cosgrove, B. D., Gersbach, C. A., & Saha, K. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-122019-121602 · Cited by 11
Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells
Kiaie, S. H., Salehi‐Shadkami, H., Sajadi, S. M. S., Gharehchelou, B., & Zangi, A. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145854 · Cited by 14
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders
Buffa, V., Vargas, J. R. A., Galy, A. H. M., Spinozzi, S., & Rocca, C. J. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.997142 · Cited by 12
MicroRNA therapeutics and nucleic acid nano-delivery systems in bacterial infection: a review
Li, Z., Lei, Z., Cai, Y., Cheng, D., & Sun, T. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00694h · Cited by 9
Delivery of nucleic acid drugs for tumor therapy: Opportunities and challenges
Sun, D., Tan, W., Zhao, J., Tian, Y., Li, S., Zhang, Z., Dong, X., Liu, X., Liu, N., Jiao, P., et al. (2024) · Fundamental Research · doi:10.1016/j.fmre.2023.11.020 · Cited by 15
Nanomaterials for intelligent CRISPR-Cas tools: improving environment sustainability
Bahl, E., Jyoti, A., Singh, A., Siddqui, A., Upadhyay, S. K., Jain, D., Shah, M. P., & Saxena, J. (2024) · Environmental Science and Pollution Research · doi:10.1007/s11356-024-32101-x · Cited by 10
Manipulation of genes could inhibit SARS-CoV-2 infection that causes COVID-19 pandemics
Banerjee, A., Mukherjee, S., & Maji, B. K. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211008106 · Cited by 9
Park, J. H., Choi, Y., Lim, C.-W., Park, J.-M., Yu, S.-H., Kim, Y., Han, H. J., Kim, C., Song, Y., Kim, C. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.27.190561 · Cited by 9
Screening lipid nanoparticles using DNA barcoding and qPCR
Liu, D., Wang, X., Xu, L., Al-Delfi, Z., Mekonnen, Z. A., Gao, S., Grubor‐Bauk, B., & Zhao, C. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114598 · Cited by 11
Gorachinov, F., Mraiche, F., Moustafa, D. A., Hishari, O., Ismail, Y., Joseph, J. M., Crcarevska, M. S., Dodov, M. G., Geškovski, N., & Goračinova, K. (2023) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.14.23 · Cited by 8
Francisco, V., Rebelo, C., Rodrigues, A. F., Blersch, J., Fernandes, H., & Ferreira, L. (2020) · Methods · doi:10.1016/j.ymeth.2020.12.002 · Cited by 8
Pandey, S., Bednarz, P., Oberli, M. A., & Omid Veiseh, A. (2024) · Nano Research · doi:10.1007/s12274-024-6862-4 · Cited by 8
Szebeni, J., & Koller, Á. (2025) · Vaccines · doi:10.3390/vaccines13080855 · Cited by 13
Silica nanoparticles as advanced platforms for nucleic acid delivery
Fanárraga, M. L., & García‐Hevia, L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102921 · Cited by 10
Encapsulating In Vitro Transcribed circRNA into Lipid Nanoparticles Via Microfluidic Mixing
Juchem, M., Cushman, S., Lu, D., Chatterjee, S., Bär, C., & Thum, T. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3678-7_14 · Cited by 8
Hsia, T., & Chen, Y. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114234 · Cited by 7
Approaches towards biomaterial-mediated gene editing for cancer immunotherapy
Shannon, S. R., Ben‐Akiva, E., & Green, J. J. (2022) · Biomaterials Science · doi:10.1039/d2bm00806h · Cited by 7
Kimura, S., & Harashima, H. (2024) · BioDrugs · doi:10.1007/s40259-024-00647-4 · Cited by 9
Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells
Trines, M. M., Hoorn, D., Hofstraat, S. R. J., Zwolsman, R. C., Anbergen, T., Versteeg, I., van Elsas, Y., Deckers, J., Hendrikx, M., Kleuskens, T., et al. (2025) · Advanced Materials · doi:10.1002/adma.202504830 · Cited by 11
Han, Y., Wang, Y., Gao, X., Lei, Y., Li, Y., & Tang, Z. (2026) · Cancer Nexus · doi:10.1002/cnx2.70021 · Cited by 10
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Recent strategies for enhanced delivery of mRNA to the lungs
Heiser, B. J., Veyssi, A., & Ghosh, D. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2485669 · Cited by 8
CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy
Huang, L., Yang, C., Chen, Y., Deng, H., Liao, Z., & Xiao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.045 · Cited by 9
Therapeutic significance of nano- and biosensor technology in combating SARS-CoV-2: a review
Abid, R., Shahzad, M. K., Sulaman, S. M., Faheem, M. Q., Naeem, M., Khan, R., Khalil, A. A. K., Haider, A., Ahmad, B. M., Gul, R., et al. (2022) · Applied Nanoscience · doi:10.1007/s13204-022-02465-y · Cited by 6
Ma, P., Ma, H., Li, J., Bi, W., Zhang, S., Hou, W., & Xu, H. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104532 · Cited by 8
Chen, F., Liu, Q., Xiong, Y., & Xu, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.984981 · Cited by 8
Optimizing Nucleic Acid Delivery Systems through Barcode Technology
Park, S., Kim, M., & Lee, J. W. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00602 · Cited by 6
SORTing the Fate of Nanodelivery Systems
Saw, P. E., & Kong, N. (2021) · BIO Integration · doi:10.15212/bioi-2021-0005 · Cited by 5
Seshire, A., Duan, Y., & Lang, K. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_723 · Cited by 4
Designing Nanoparticle Surfaces with DNA Barcodes for Accurate In Vivo Quantification
Lekuti, A. A., Li, V. Y. C., Malekjahani, A., Ahmed, S., Mladjenovic, S. M., Macduff, M. G. G., & Chan, W. C. W. (2025) · JACS Au · doi:10.1021/jacsau.5c00475 · Cited by 6
Sasaki, S., Ogawa, H., Katoh, H., & Honda, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063523 · Cited by 5
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
Michalaki, E., Chin, R. L., Jeong, K., Qi, Z., Liebman, L. N., González-Vargas, Y., Echeverri, E. S., Paunovska, K., Muramatsu, H., Pardi, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.31.605343 · Cited by 4
Self-citationEmerging Approaches for the Discovery of Lipid-Based RNA Delivery Systems
Meers, P. R. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091231 · Cited by 5
Michalaki, E., Jeong, K., Chin, R. L., Qi, Z., Liebman, L. N., González-Vargas, Y., Echeverri, E. S., Paunovska, K., Muramatsu, H., Pardi, N., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c12080 · Cited by 8
Self-citationSlaughter, K. V., Li, X. O., & Shoichet, M. S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115758 · Cited by 3
The time course of in vivo cellular responses to LNPs
Loughrey, D., Paunovska, K., Echeverri, E. S., Tiegreen, K. E., & Dahlman, J. E. (2025) · Chemical Communications · doi:10.1039/d4cc06659f · Cited by 4
Self-citationImproving the Efficacy of Cancer mRNA Vaccines
Kirtane, A. R., & Traverso, G. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000764 · Cited by 3
A high-throughput approach of screening nanoparticles for targeted delivery of mRNA
Khirallah, J., & Xu, Q. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100572 · Cited by 3
Non-viral vector-based genome editing for cancer immunotherapy
Fang, T., & Chen, G. (2024) · Biomaterials Science · doi:10.1039/d4bm00286e · Cited by 4
Nanodelivery systems for gene editing drugs
Zhang, Y., & Ping, Y. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2025-0178 · Cited by 3
Rewriting the script: gene therapy and genome editing for von Willebrand Disease
Barraclough, A., Bär, I., van Duijl, T. T., Fijnvandraat, K., Eikenboom, J. C. J., Leebeek, F. W. G., Bierings, R., Voorberg, J., & Trasanidou, D. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1620438 · Cited by 4
Nelson, B. C., & Borgos, S. E. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0024 · Cited by 3
Mucosal and transdermal delivery strategies for mRNA: Transforming the clinical applications
Wang, L., & Deng, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114221 · Cited by 2
Lipid nanoparticle GM-CSF replacement for autoimmune pulmonary alveolar proteinosis
Lian, L., Jang, B., Huayamares, S. G., Shakked, A., Gentry, K., Zenhausern, R., Radmand, A., Echeverri, E. S., Parihar, V. C., Guerrero-Ferreira, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511483123 · Cited by 2
Self-citationsgRNA amount is a limiting factor in adenine base editing using RNA LNPs
Birkenshaw, A., Thomson, T., Truong, M. P., Komaki, Y., Ramsden, N., Timpano, A., Huang, C., Blakney, A. K., Kurek, D. Z., Kulkarni, J. A., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102909 · Cited by 3
Winkeljann, B., Lapuhs, P., Alonso, M. J., & Kımna, C. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114911 · Cited by 3
Quantitative Determination of Intracellular Bond Cleavage
Walker, J. A., Sorkin, M. R., & Alabi, C. A. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_14 · Cited by 2
Proteases as Biological Bits for Programmable MedicinePreprint
Holt, B. A., & Kwong, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/607895 · Cited by 2
Advanced drug delivery systems for enhancing the efficacy of RNA-based therapeutics
Alhabib, N. A., Almaniea, M. A., Alehaidib, S. M., Almansour, M. A., Aldosary, M. S., Almegbel, M. T., Alsubaie, S. A., & Alzahrani, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15029 · Cited by 1
Multiplexed spatial screening of lipid-based nanoparticles for extrahepatic messenger RNA targeting
Enzlein, T., Schumacher, J., Geisel, A., Keller, F., Houben, A., Walzer, K. C., Rittel, M. F., Fröhlich, B., Cairns, J. L., Cordes, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114728 · Cited by 2
Multiscale modeling guided potency assessment of mRNA-lipid nanoparticles
Yang, Y., Qiu, Y., Wang, K., Liu, Y., Sanyal, G., Whitford, P. C., Rouhanifard, S. H., & Xie, W. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102965 · Cited by 4
Zhou, J., Li, N., Liu, R., Kabanov, A. V., Polacheck, W. J., Nguyen, J., & Cao, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115157 · Cited by 4
Artificial intelligence in the rational design of lipid nanoparticles for mRNA therapeutics
Zhao, H., Xu, J., Gao, X., Zhu, J., & He, Z. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100006 · Cited by 6
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Self-citationJiang, K., Shao, B., Li, R., Liang, T., You, C., Wang, L., Cen, J., Tan, J., Zhang, Y., Chen, M., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3823572 · Cited by 1
Hani, U. E., Sulaiman, M., Zafar, H., & Raza, F. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01950a · Cited by 1
Application of quantitative and engineering biology in mRNA gene therapy
Xiang, H., Ke, L., Yang, X., Guo, J., Yang, W., & Hu, Y. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2020-0476 · Cited by 2
A Peptide Barcode Based Approach for Efficient in vivo Screening of RNA Delivery SystemsPreprint
Odunze, U., Rustogi, N., Devine, P., Miller, L., Pereira, S., Vashist, S., Snijder, A., Corkill, D. J., Sabirsh, A., Douthwaite, J. A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2386865/v1 · Cited by 1
Multi-Scale Kinetics Modeling and Advanced Assay for mRNA-Lipid Nanoparticle Potency AssessmentPreprint
Yang, Y., Qiu, Y., Wang, K., Liu, Y., Sanyal, G., Whitford, P. C., Rouhanifard, S. H., & Xie, W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.29.679406 · Cited by 1
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseasesPreprint
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D. N., Grindel, B. I., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L. K., Goedland, M., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-90150/v1
Lipid Nanoparticles to Harness the Therapeutic Potential of mRNA for Cancer Treatment
Guevara, M. L., Persano, F., & Persano, S. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_14
Advanced Therapy Medicinal Products: Clinical, Non-clinical, and Quality Considerations
Mastrobattista, E., Doevendans, E., van Til, N. P., Kemp, V., de Vrij, J., & Hoogendoorn, K. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_14 · Cited by 1
Cancer Vaccines Based on mRNA: Hype or Hope?
de Mey, W., Autaers, D., Bertazzon, G., Esprit, A., Aragon, M. M., Franceschini, L., & Breckpot, K. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch13
Advances of mRNA vaccines in genitourinary cancers
Shen, Y.-M., Wan, F., Xu, H., Yu, L., Huang, S., Ye, D., & Dai, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189427 · Cited by 1
RNA therapeutic delivery systems—advances and challenges
Fiedorowicz, K., & Przysiecka, Ł. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33064-3.00001-3 · Cited by 1
Aguilà, M., Cnubben, N. H. P., Parfitt, D. A., Albuquerque, B., de Visser, P. C., Molendijk, M., Marques, L., van Berkel, M., & Platenburg, G. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25280-1 · Cited by 1
Zhang, H., Chen, D., Xue, S., Liu, Z., Yang, X., Zhang, C., Li, D., & Zhang, D. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01272 · Cited by 1
Amphiphilic guanidine-based lipids enhance mRNA delivery and immune activation
Wei, Q., Li, R., Fan, J., Xu, M., Yuan, P., Liu, J., Wang, Q., Shen, Y., Slater, N. K. H., & Tang, J. (2026) · Biomaterials Science · doi:10.1039/d6bm00068a
Future trends in LNP-mRNA therapeutics
Singh, A. K., Singh, B., & Mishra, S. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00014-8
Advanced lipid nanoparticles for targeted nucleic acid delivery
Deng, Y., Chen, M., Zhou, X., Luo, T., Guo, J., Giles, A., Mourin, T. T., & Chen, G. (2026) · Nano Research · doi:10.26599/nr.2026.94908809
Focused ultrasound is poised to take non-viral gene therapies to the blood-brain barrier—And beyond
Gordon, E. N., Debski, A. C., Breza, V. R., Hoch, M. R., Anwar, N. Z., Imomnazarov, K., Batts, A. J., DeWitt, M. R., Sheybani, N., & Price, R. J. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100461 · Cited by 1
Liu, B., Klatt, D., Harris, C. E., McGuinness, M. K., Brendel, C., & Williams, D. A. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag500
Arral, M. L., Chaudhary, N., Fein, K. C., Newby, A. N., Yerneni, S. S., Melamed, J. R., LoPresti, S. T., Petersen, D. M. S., & Whitehead, K. A. (2026) · Drug Delivery and Translational Research · doi:10.21203/rs.3.rs-9763025/v1 · Cited by 1
Abdel-Hamed, M. R., Saber, S., Elmorsy, E. A., Elesawy, B. H., Amer, M. M., Abdel-Moneim, A.-M. H., Firgany, A. E. D., Mohamed, E. A., Eltayeb, H., Hassan, A. M., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1901757
Ou, B., Tang, X., Qian, S., Chen, B., Fang, S., Su, J., Sheng, X., Feng, J., Yuan, Z., & Zhang, J. (2026) · Small · doi:10.1002/smll.74730
Jiang, K., Shao, B., Li, R., Liang, T., You, C., Wang, L., Cen, J., Tan, J., Zhang, Y., Chen, M., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.3823572
Xiao, S., Liang, Y., Zhang, Y., Liang, L., Xu, B., Mu, X., Zhao, S., & Tian, J. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.346106
Metadata
- Authors
- Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., Munnilal Tiwari, P., Kirschman, J. L., Willett, N., Jang, Y. C., Santangelo, P. J., Bryksin, A. V., & Dahlman, J. E.
- Affiliations
- Georgia Institute of Technology (US)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332;
- Corresponding author
- Dahlman, James E.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-10
- Volume
- 115
- Issue
- 42
- Pages
- E9944-E9952
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6196543
- OpenAlex
- W2893976143
- Cited by
- 313
- References
- 45
- Citations by year
- 2026: 37 · 2025: 45 · 2024: 46 · 2023: 44 · 2022: 58 · 2021: 31 · 2020: 36 · 2019: 16
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-11-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (T32EB021962, T32GM008433, 5T32EB006343)
- Cystic Fibrosis Foundation (DAHLMA15XX0)
- Parkinson's Disease Foundation (PDF-JFA-1860)
- Bayer (AGE DTD)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- lipid nanoparticles, mRNA delivery, endothelial cells, CRISPR/Cas9 genome editing, siRNA delivery, single guide RNA, hepatocytes
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Animals, Cells, Cultured, Humans, Lipids, Mice, Inbred C57BL, RNA, Messenger, Gene Transfer Techniques, Hepatocytes, Endothelial Cells, Mice, Nanoparticles, High-Throughput Screening Assays, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.